Sanaria (original) (raw)
Sanaria is a biotechnology company developing vaccines protective against malaria and other infectious diseases as well as related products for use in malaria research. Sanaria’s vaccines are based on the use of the sporozoite (SPZ) stage of the malaria parasite, Plasmodium, as an immunogen, and as a platform technology for liver-vectored gene delivery. SPZ are normally introduced into humans by mosquito bite where they migrate to the liver and further develop to liver stages, and eventually back into the blood stream where the parasite infects red blood cells (RBC) and causes malaria. Plasmodium falciparum is the species responsible for more than 95% deaths caused by malaria. The WHO estimates there were 241 million clinical cases and 627,000 deaths in 2020 alone.
| Property | Value |
|---|---|
| dbo:abstract | Sanaria is a biotechnology company developing vaccines protective against malaria and other infectious diseases as well as related products for use in malaria research. Sanaria’s vaccines are based on the use of the sporozoite (SPZ) stage of the malaria parasite, Plasmodium, as an immunogen, and as a platform technology for liver-vectored gene delivery. SPZ are normally introduced into humans by mosquito bite where they migrate to the liver and further develop to liver stages, and eventually back into the blood stream where the parasite infects red blood cells (RBC) and causes malaria. Plasmodium falciparum is the species responsible for more than 95% deaths caused by malaria. The WHO estimates there were 241 million clinical cases and 627,000 deaths in 2020 alone. Sanaria has developed the technology to grow and harvest aseptic, purified Plasmodium falciparum (Pf) SPZ and formulate them as vaccines for human use. Sanaria's first generation vaccine is called Sanaria® PfSPZ Vaccine, and uses radiation attenuated (weakened) SPZ, that cannot divide or cause disease, to induce these protective immune responses in the liver. The next generation vaccines are attenuated differently. Sanaria® PfSPZ-CVac, uses infectious PfSPZ administered along with antimalarial drugs to develop through the liver stage and be killed before infecting RBCs and induce protective immunity. Sanaria® PfSPZ-LARC2 Vaccine is genetically-attenuated to arrest (halt development) late in the liver stages of the life cycle. Sanaria is also developing a vaccine that will prevent malaria caused by Plasmodium vivax, the second most important type of malaria parasite worldwide and is expanding its PfSPZ platform to develop vaccines for other diseases where an immune response in the liver may be beneficial, such as chronic hepatitis. In addition to vaccines,Sanaria produces PfSPZ products for clinical research. Sanaria® PfSPZ Challenge consists of purified, aseptic, infectious PfSPZ and is used for controlled human malaria infections to assess the efficacy of vaccines and drugs against malaria, and acquired or induced immunity and resistance to malaria infection. (en) |
| dbo:foundingYear | 2003-01-01 (xsd:gYear) |
| dbo:keyPerson | dbr:Stephen_L._Hoffman |
| dbo:location | dbr:Rockville,_Maryland |
| dbo:numberOfEmployees | 65 (xsd:nonNegativeInteger) |
| dbo:wikiPageExternalLink | http://www.dzif.de/en/ http://www.sanaria.com/index.php%3Fs=1 https://www.concordia.net/organization/bioko-island-malaria-elimination-program/ https://www.concordia.net/partnerships/awards/p3impactaward/ http://www.sanaria.com |
| dbo:wikiPageID | 45219879 (xsd:integer) |
| dbo:wikiPageLength | 29974 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1116844486 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Rockville,_MD dbr:Rockville,_Maryland dbr:Bill_&_Melinda_Gates_Foundation dbr:Bill_and_Melinda_Gates_Foundation dbr:United_States_Department_of_Defense dbr:United_States_Patent_and_Trademark_Office dbr:University_of_Tübingen dbr:Vaccines dbc:Biotechnology_companies_of_the_United_States dbc:Companies_established_in_2003 dbr:SARS-CoV-2 dbr:Montgomery_County,_Maryland dbr:Concordia_Summit dbr:Tanzania_Commission_for_Science_and_Technology dbr:Leiden_University dbr:Malaria dbr:Aseptic dbr:Plasmodium_falciparum dbr:FDA dbr:Federal_Council_(Switzerland) dbr:Noble_Energy dbr:PATH_(global_health_organization) dbr:Marathon_Oil dbr:Sporozoite dbr:FDA_Fast_Track dbr:Antimalarial_drugs dbr:National_Institute_of_Allergy_and_Infectious_Diseases dbr:National_Institutes_of_Health dbr:Radboud_University_Nijmegen dbr:Seattle_Children's dbr:Small_Business_Innovation_Research dbr:Plasmodium_vivax dbr:Immunogen dbr:Swiss_Tropical_and_Public_Health_Institute dbr:PfSPZ_Vaccine dbr:Stephen_L._Hoffman dbr:Prophylactic |
| dbp:foundation | 2003 (xsd:integer) |
| dbp:homepage | http://www.sanaria.com |
| dbp:industry | Biotechnology (en) |
| dbp:keyPeople | dbr:Stephen_L._Hoffman |
| dbp:location | Rockville, Maryland, United States (en) |
| dbp:name | Sanaria Inc. (en) |
| dbp:numEmployees | 65 (xsd:integer) |
| dbp:products | Malaria Vaccines, COVID-19 Vaccines (en) |
| dbp:type | Corporation (en) |
| dbp:wikiPageUsesTemplate | dbt:Infobox_company dbt:Reflist dbt:Short_description |
| dct:subject | dbc:Biotechnology_companies_of_the_United_States dbc:Companies_established_in_2003 |
| gold:hypernym | dbr:Company |
| rdf:type | owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation |
| rdfs:comment | Sanaria is a biotechnology company developing vaccines protective against malaria and other infectious diseases as well as related products for use in malaria research. Sanaria’s vaccines are based on the use of the sporozoite (SPZ) stage of the malaria parasite, Plasmodium, as an immunogen, and as a platform technology for liver-vectored gene delivery. SPZ are normally introduced into humans by mosquito bite where they migrate to the liver and further develop to liver stages, and eventually back into the blood stream where the parasite infects red blood cells (RBC) and causes malaria. Plasmodium falciparum is the species responsible for more than 95% deaths caused by malaria. The WHO estimates there were 241 million clinical cases and 627,000 deaths in 2020 alone. (en) |
| rdfs:label | Sanaria (en) |
| owl:sameAs | freebase:Sanaria yago-res:Sanaria wikidata:Sanaria https://global.dbpedia.org/id/26Hz4 |
| skos:closeMatch | http://www.grid.ac/institutes/grid.280962.7 |
| prov:wasDerivedFrom | wikipedia-en:Sanaria?oldid=1116844486&ns=0 |
| foaf:homepage | http://www.sanaria.com |
| foaf:isPrimaryTopicOf | wikipedia-en:Sanaria |
| foaf:name | Sanaria Inc. (en) |
| is dbo:wikiPageWikiLink of | dbr:Malaria_vaccine dbr:PfSPZ_Vaccine dbr:Peter_Gottfried_Kremsner dbr:Stephen_L._Hoffman |
| is foaf:primaryTopic of | wikipedia-en:Sanaria |